CAPÍTULO 3: Consenso en temas de interés general relacionados con el tratamiento de la artritis reumatoidea
Resumen
En esta segunda parte de las recomendaciones, los expertos consideramos ciertos temas de interés general para incluir en la revisión sistemática de la literatura (RSL) y por sus características se analizaron de forma cualitativa (Tabla 1 y Material suplementario-Apéndice 4: capítulos 1-20).Citas
I. Deane KD, Striebich C, Feser M, Demoruelle K, Moss L, Bemis E, et al. Hydroxychloroquine does not prevent the future development of rheumatoid arthritis in a population with baseline high levels of antibodies to citrullinated protein antigens and absence of inflammatory arthritis: interim analysis of the StopRA Trial [abstract].Arthritis Rheumatol. 2022;74 (Suppl 9);1604.
II. Bos WH, Dijkmans BAC, Boers M, van de Stadt RJ, van Schaardenburg D. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann Rheum Dis. 2010;69(3):571-4.
III. van Boheemen L, Turk S, van Beers-Tas M, Bos W, Marsman D, Griep EN, et al. Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial. RMD Open. 2021;7(1):e001591.
IV. Cope AP, Jasenecova M, Vasconcelos JC, Filer A, Raza K, Qureshi S, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, doubleblind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. 2024;403(10429):838-49.
V. Rech J, Ostergaard M, Tascilar K, Hagen M, Valor Mendez L, et al. Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebocontrolled ARIAA Study in RA-at Risk Patients. Arthritis Rheumatol. 2021;73(suppl 10)#0455.
VI. Gerlag DM, Safy M, Maijer KI, Wai Tang M, Tas SW, Starmans-Kool MJF, et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann Rheum Dis. 2019;78(2):179-85.
VII. Krijbolder DI, Verstappen M, van Dijk BT, Dakkak YJ, Burgers LE, Boer AC, et al. Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proofof-concept trial. Lancet. 2022;400(10348):283-94.
VIII. van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HMJ, et al. Efficacy of Methotrexate Treatment in Patients With Probable Rheumatoid Arthritis. Arthritis Rheum. 2007;56(5):1424-32.
IX. Machold KP, Landewé R, Smolen JF, Stamm TA, van der Heijde DM, Verpoort KN. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, PBO-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis. 2010;69(3):495-502.
X. Verstappen SM, McCoy MJ, Roberts C, Dale NE, Hassell AB, Symmons DMP, the STIVEA investigators. Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis. 2010;69(3):503-9.
XI. Emery P, Durez P, Dougados M, Legerton CW, Becker J-C, Vratsano G. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010;69(3):510-6.
XII. van Eijk IC, Nielen MMJ, van der Horst-Bruinsma I, Tijhuis GJ, Boers M, Dijkmans BAC, et al. Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial. Rheumatology (Oxford). 2012;51(4):686-94.
XIII. Heimans L, Wevers-de Boer KVC, Visser K, Goekoop RJ, van Oosterhout M, Harbers JB, et al. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis. 2014 ;73(7):1356-61.
XIV. Rech J, Tascilar K, Hagen M, Kleyer A, Manger B, Schoenau V, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024;403(10429):850-9.
XV. van Mulligen E, Bour SS, Goossens LMA, de Jong PHP, Rutten-van Mölken M, van der Helm-van Mil A. Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial. Ann Rheum Dis. 2025;84(1):68-76.
XVI. Dumoulin QA, Krijbolder DI, Visser K, Lard LR, van der Helm-van Mil AHM. Development of rheumatoid arthritis after methotrexate in anticitrullinated protein antibody-negative people with clinically suspect arthralgia at risk of rheumatoid arthritis: 4-year data from the TREAT EARLIER trial. Lancet Rheumatol. 2024;6(12):e827-e836.
XVII. van Nies JAB, Krabben A, Schoones JW, Huizinga TWJ, Kloppenburg M, van der Helm-van Mil AHM. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73(5):861-70.
XVIII. Combe B, Landewé R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017;76(6):948-59.
XIX. Hughes CD, Scott D, Ibrahim F, TITRATE Programme Investigators. Intensive therapy and remissions in rheumatoid arthritis: a systematic review. BMC Musculoskelet Disord. 2018;19(1):389.
XX. Mian A, Ibrahim F, Scott DL. A systematic review of guidelines for managing rheumatoid arthritis. BMC Rheumatol. 2019;3:42.
XXI. Sanmartí R, Tornero J, Narváez J, Muñoz A, Garmendia E, Ortiz AM, et al. Eficacia y seguridad de los glucocorticoides en la artritis reumatoidea: revisión sistemática de la literatura. Reumatol Clin. 2020;16(3):222-8.
XXII. Calvo Alén J, Pérez T, Romero Yuste S, Ferraz-Amaro I, Alegre Sancho JJ, Pinto Tasende JA, et al. Eficacia y seguridad de la terapia combinada con fármacos modificadores de la enfermedad sintéticos en la artritis reumatoidea: revisión sistemática de la literatura. Reumatol Clin. 2020;16(5 Pt 1):324-32.
XXIII. Kerschbaumer A, Sepriano A, Bergstra SA, Smolen JS, van der Heijde D, Caporali R, et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023;82(1):95-106.
XXIV. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 2000;43(1):22-9.
XXV. Nell VPK, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43(7):906-14.
XXVI. Finckh A, Liang MH, Mugica van Herckenrode C, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum. 2006;55(6):864-72.
XXVII. Raza K, Saber TP, Kvien TK, Tak PP, Gerlag DM. Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials. Ann Rheum Dis. 2012;71(12):1921-3.
XXVIII. van Nies JAB, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AHM. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis. 2015;74(5):806-12.
XXIX. Burgers LE, Raza K, van der Helm-van Mil AH. Window of opportunity in rheumatoid arthritis - definitions and supporting evidence: from old to new perspectives. RMD Open. 2019;5(1):e000870.
XXX. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis.Ann Intern Med. 2007;146(11):797-808.
XXXI. Kanters S, Druyts E, Mills EJ, Thorlund K. What drives the comparative effectiveness of biologics vs. methotrexate in rheumatoid arthritis? Meta-regression and graphical inspection of suspected clinical factors. Rheumatology (Oxford). 2014;53(7):1264-73.
XXXII. Muñoz-Fernández S, Otón-Sánchez T, Carmona L, CalvoAlén J, Escudero A, Narváez J, et al. Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence. Rheumatol Int. 2018;38(12):2289-96.
XXXIII. Edwards CJ, Kiely P, Arthanari S, Kiri S, Mount J, Barry J, et al. Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review. Rheumatol Adv Pract. 2019;3(1):rkz002.
XXXIV. Narváez J, Otón T, Calvo-Alén J, Escudero-Contreras A, Muñoz-Fernández S, Rodríguez-Heredia JM, et al. Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey. Joint Bone Spine. 2021;88(4):105172.
XXXV. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18.
XXXVI. Abdelhafiz D, Baker T, Glascow DA, Abdelhafiz A. Biomarkers for the diagnosis and treatment of rheumatoid arthritis - a systematic review. Postgrad Med. 2023;135(3):214-23.
XXXVII. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114-23.
XXXVIII. Fleischmann R, van Adelsberg J, Lin J, da Rocha CastelarPinheiro G, Brzezicki J, Hrycaj P, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69(2):277-90.
XXXIX. Nagy G, Roodenrijs N, Welsing, P, Kedves M, Hamar A, van der Goes M, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022;81(1):20-33.
XL. Peluso G, Michelutti A, Bosello S, Gremese E, Tolusso B, Ferraccioli G. Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. Ann Rheum Dis. 2011;70(1):172-5.
XLI. Saleem B, Brown AK, Quinn M, Karim Z, Hensor EMA, Conaghan P, et al. Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. Ann Rheum Dis. 2012;71(8):1316-21.
XLII. Marks JL, Holroyd CR, Dimitrov BD, Armstrong RD, Calogeras A, Cooper C, et al. Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-tumor necrosis factor therapy? Arthritis Care Res (Hoboken). 2015;67(6):746-53.
XLIII. Naredo E, Valor L, De la Torre I, Montoro M, Bello N, Martínez-Barrio J, et al. Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis. Rheumatology (Oxford). 2015;54(8):1408-14.
XLIV. Valor L, Garrido J, Martínez-Estupiñán L, HernándezFlórez D, Janta I, López-Longo FJ, et al. Identifying markers of sustained remission in rheumatoid arthritis patients on long-term tapered biological diseasemodifying antirheumatic drugs. Rheumatol Int. 2018;38(8):1465-70.
XLV. Alivernini S, Peluso G, Fedele AL, Tolusso B, Gremese E, Ferraccioli G. Tapering and discontinuation of TNF-aα blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. Arthritis Res Ther. 2016;18:39.
XLVI. Janta I, Valor L, De la Torre I, Martínez-Estupiñán L, Nieto JC, Ovalles-Bonilla JG, et al. Ultrasound-detected activity in rheumatoid arthritis on methotrexate therapy: Which joints and tendons should be assessed to predict unstable remission? Rheumatol Int.
;36(3):387-96.
XLVII. El Miedany Y, El Gaafary M, Youssef S, Ahmed I, Bahlas S, Hegazi M, et al. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clin Rheumatol. 2016;35(12):2915-23.
XLVIII. Han J, Geng Y, Deng X, Zhang Z. Risk factors of flare in rheumatoid arthritis patients with both clinical and ultrasonographic remission: a retrospective study from China. Clin Rheumatol. 2017;36(8):1721-7.
XLIX. Paulshus Sundlisaeter N, Olsen IC, Aga A-B, Hammer HB, Uhlig T, Siré E Van Der Heijde D, et al. Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. Rheumatology (Oxford). 2018;57(11):2022-31.
L. Filippou G, Sakellariou G, Scirè CA, Carrara G, Rumi F, Bellis E, et al. The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology Group for Ultrasound: The STARTER study. Ann Rheum Dis. 2018;77(9):1283-9.
LI. Mollerach F, Marin J, Zacariaz J, Scolnik M, Rosa J, Ruta S, et al. Tenosinovitis subclínica detectada por ecografía en pacientes con artritis reumatoidea en remisión clínica sostenida. Rev Arg Reumatol. 2018;29(2):28-33.
LII. Zufferey P, Scherer A, Nissen MJ, Ciurea A, Tamborrini G, Brulhart L, et al. Can ultrasound be used to predict loss of remission in patients with RA in a real-life setting? A multicenter cohort study. J Rheumatol. 2018;45(7):887-94.
LIII. Yoshida S, Kotani T, Kimura Y, Matsumura Y, Yoshikawa A, Tokai N, et al. Efficacy of abatacept tapering therapy for sustained remission in patients with rheumatoid arthritis: Prospective single-center study. Int J Rheum Dis. 2019;22(1):81-9.
LIV. Terslev L, Heegaard Brahe C, Lund Hetland M, Georgiadis S, Ellegaard K, Juul L, et al. Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission. Rheumatology (Oxford). 2021;60(12):5549-59.
LV. Gul HL, Matteo A Di, Mankia K, Wu J, Ponchel F, Emery P. Can biomarkers predict successful tapering of conventional disease-modifying therapy in rheumatoid arthritis patients in stable remission? Clin Exp Rheumatol. 2023;41(1):126-36.
LVI. Haavardsholm E, Aga A-B, Olsen IC, Lillegraven S, Hammer HB, Uhlig T, et al. Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ. 2016;354:i4205.
LVII. Sundin U, Aga A-B, Skare Ø, Nordberg L, Uhlig T, Hammer H, et al. Ultrasound versus conventional treat-to-target strategies in early rheumatoid arthritis: magnetic resonance imaging outcome data from a 2-year Randomized Controlled Strategy Trial. Arthritis Rheumatol. 2019;71(Suppl. 10):441-2.
LVIII. Sundin U, Paulshus Sundlisater N, Aga A-B, Sexton J, Bugge Nordberg L, Berner Hammer H, et al. Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treatto-target strategy. RMD Open. 2021;7(1):e001525.
LIX. Dale J, Stirling A, Zhang R, Purves D, Foley J, Sambrook M, et al. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Ann Rheum Dis. 2016;75(6):1043-50.
LX. Ten Cate DF, Luime J, Swen N, Gerards AH, De Jager M, Basoski N, et al. Role of ultrasonography in diagnosing early rheumatoid arthritis and remission of rheumatoid arthritis. A systematic review of the literature.Arthritis Res Ther. 2013;15(1):R4.
LXI. Nguyen H, Ruyssen-Witrand H, Gandjbakhch F, Constantin A, Foltz V, Cantagrel A. Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. Rheumatology (Oxford). 2014;53(11):2110-8.
LXII. Han J, Geng Y, Deng X, Zhang Z. Subclinical synovitis assessed by ultrasound predicts flare and progressive bone erosion in rheumatoid arthritis patients with clinical remission. A systematic review and metaanalysis. J Rheumatol. 2016;43(11):2010-8.
LXIII. Iwamoto T, Ikeda K, Hosokawa J, Yamagata M, Tanaka S, Norimoto A, et al. Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total grayscale and power Doppler scores that represent residual synovial inflammation before discontinuation. Arthritis Care Res (Hoboken). 2014;66(10): 1576-81.
LXIV. Schlager L, Loiskandl M, Aletaha D, Radner H. Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. Rheumatology (Oxford). 2020;59(2):324-34.
LXV. Silvagni E, Zandonella Callegher S, Mauric E, Chiricolo S, Schreiber N, Tullio A, et al. Musculoskeletal ultrasound for treating rheumatoid arthritis to target. A systematic literature review. Rheumatology (Oxford). 2022;61(12):4590-602.
LXVI. Betancur J, Martínez JP, Tobón GJ, Ocho CD. El papel de la ultrasonografía para la evaluación subclínica de la artritis reumatoidea en remisión. Revisión sistemática de la literatura. Rev Colomb Reumatol. 2015;22(1):31-46.
LXVII. Colebatch A, Edwards CJ, Østergaard M, van der Heijde S, Balint P, D’Agostino M-A, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72(6):804-14.
LXVIII. Chung SW, Choi JY, Lee SH, Song R, Yang HI, Hong SJ, et al. Predicting imaging remission in rheumatoid arthritis a case-control ultrasound study. J Korean Med Sci. 2020;35(31):e260.
LXIX. Saag KG, Criswell LA, Sems KM, Nettleman MD, Kolluri S. Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness. Arthritis Rheum. 1996;39(11):1818-25.
LXX. Criswell LA, Saag KG, Sems KM, Welch V, Shea B, Wells G, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;1998(2):CD001158.
LXXI. Gotzsche PC, Johansen HK. Short-term lowdose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev. 2004;2005(3):CD000189.
LXXII. Kirwan JR, Bijlsma JWJ, Boers M, SheaBJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. 2007;2007(1):CD006356.
LXXIII. Ruyssen-Witrand A, Fautrel B, Saraux A, Le Loët X, Pham T. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine. 2011;78(1):23-30.
LXXIV. Bakker MF, Jacobs JWG, Welsing PMJ, Verstappen SMM, Tekstra J, Ton E, et al. Estudio CAMERA-II (Computer
Assisted Management in Early Rheumatoid Arthritis trialII)). Low-dose prednisone inclusion in a methotrexatebased, tight control strategy for early rheumatoid arthritis:
a randomized trial. Ann Intern Med. 2012;156(5):329-39.
LXXV. Palmowski A, Nielsen SM, Boyadzhieva Z, Schneider A, Pankow A, Hartman L, et al. Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and metaanalysis.Rheumatology (Oxford). 2023;62(8):2652-60.
LXXVI. Buttgereit F, da Silva JAP, Boers M, Burmester G-R, Cutolo M, Jacobs J, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61(8):718-22.
LXXVII. Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkinet J, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis. 2004;63(7):797-803.
LXXVIII. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafströmet I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 2005;52(11):3360-70.
LXXIX. Boers M, Hartman L, Opris-Belinski D, Bos R, Kok MR, Da Silva J, et al. Estudio GLORIA (Glucocorticoid LOwdose in Rheumatoid Arthritis). Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Ann Rheum Dis. 2022;81(7):925-36.
LXXX. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very lowdose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(11):3371-80.
LXXXI. Brance ML, Larroudé MS, Zamora NV, Bagur A, Graf CE, Giacoia E, et al. Argentine guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis in postmenopausal women and men aged 50 years and older. J Clin Rheumatol. 2023;29(5):e59-e70.
LXXXII. Glennon V, Whittle SL, Hill CL, Johnston RV, Avery JC, Grobler L, et al. Short-term glucocorticoids for flares in people with rheumatoid arthritis receiving diseasemodifying anti-rheumatic drugs (DMARDs) (Protocol). Cochrane Database Syst Rev. 2021:2021(11): CD014898.
LXXXIII. Bergstra S, Sepriano A, Kerschbaumer A, van der Heijde D, Caporali R, Edwards C, et al. Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023;82(1):81-94.
LXXXIV. Fraenkel L, Bathon J, England B, St Clair B, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108-23.
LXXXV. Martínez-López JA. Systematic review: is the use of NSAIDs safe during pregnancy in women with rheumatic disease? Reumatol Clin. 2008;4(5):191-6.
LXXXVI. Martínez-López JA, Loza E, Carmona L. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol. 2009;27(4):678-84.
LXXXVII. Burmester GR, Landewé R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, et al. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(2):414-7.
LXXXVIII. Mirdamadi K, Salinas T, Vali R, Papadimitropoulos M, Piquette-Miller M. Meta-analysis of pregnancy outcomes after exposure to TNF-α inhibitors during pregnancy for the treatment of arthritic diseases. J Popul Ther Clin Pharmacol. 2018;25(1):e53-e56.
LXXXIX. Tsao NW, Rebic N, Lynd LD, De Vera MA. Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford). 2020;59(8):1808-17.
XC. Nguyen H, Ahmed K, Luo W, Flint J, Giles I. A Systematic review of the safety of non-TNF inhibitor biologic and targeted synthetic drugs in rheumatic disease in pregnancy. Semin Arthritis Rheum. 2021;51(6):1205-17.
XCI. Barenbrug L, Groen MT, Hoentjen F, van Drongelen J, van dern Reek JMPA, Joosten I, et al. Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-α during pregnancy: A systemic review and meta-analysis. J Autoimmun. 2021;122: 102676.
XCII. Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795-810.
XCIII. Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding. Part I: Standard and biologic disease modifying antirheumatic drugs and corticosteroids. Rheumatology (Oxford). 2016;55(9):1693-7.
XCIV. Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: Analgesics and other drugs used in rheumatology practice. Rheumatology (Oxford). 2016;55(9):1698-702.
XCV. Alhajeri H, Abutiban F, Al-Adsani W, Al-Awadhi A, Aldei A, AlEnizi A, et al. Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis. Rheumatol Int. 2019;39(9):1483-97.
XCVI. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020;72(4):529-56.
XCVII. Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo RM, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228-33.
XCVIII. Saavedra Salinas MÁ, Barrera Cruz A, Cabral Castañeda AR, Jara Quezada LJ, Arce-Salinas CA, Álvarez Nemegyei J, et al. Guías de práctica clínica para la atención del embarazo en mujeres con enfermedades reumáticas autoinmunes del Colegio Mexicano de Reumatología. Parte II. Reumatol Clin. 2015;11(5):305-15.
XCIX. Martínez-López JA, García-Vivar ML, Cáliz R, Freire M, Galindo M, Hernández MV, et al. Recomendaciones sobre actuaciones a seguir durante la edad fértil, el embarazo, posparto y lactancia en pacientes con enfermedades reumáticas inflamatorias y autoinmunes. Reumatol Clin. 2017;13(5):264-81.
C. Roodenrijs NMT, Hamar A, Kedves M, Nagy G, Van Laar JM, van der Heijde D, et al. Pharmacological and nonpharmacological therapeutic strategies in difficultto-treat rheumatoid arthritis. A systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open. 2021;7(1):e001512.
CI. Clowse ME, Förger F, Hwang C, Thorp J, Dolhain RJ, van Tubergen A, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76(11):1890-6.
CII. Levitsky A, Brismar K, Hafström I, Hambardzumyan K, Lourdudoss C, van Vollenhoven RF, et al. Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial. RMD Open. 2017;3(2):e000458.
CIII. Villalba-Yllan A, Navarro-Compan V, PlasenciaRodríguez C, Peiteado-López D, Bonilla-Hernán G, Nuño-Nuño L, et al. Influence of body mass index (BMI) on the disease inflammatory activity and treatment reponse in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(Suppl. 2):824.
CIV. Kaeley G, MacCarter D, Pangan A, Wang X, Kalabic J, Ranganath V. Clinical responses and synovial vascularity in obese rheumatoid arthritis patients treated with adalimumab and methotrexate. J Rheumatol. 2018;45(12):1628-35.
CV. Roodnrijs N, Hamar A, Kedves M, Nagy G, van Laar J, van der Heijde D, et al. Pharmacological and nonpharmacological therapeutic strategies in difficultto-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open. 2021;7(1):e001512.
CVI. Nusslein H, Alten R, Galeazzi M, Lorenz H, Nurmohamed M, Benson, et al. Does body mass index impact longterm retention with abatacept in patients with RA who have received at least one prior biologic agent? 2-year results from a real-world, international, prospective study. Arthritis Rheumatol. 2014;66(S10):S1088-9.
CVII. Abuhelwa A, Hopkins A, Sorich M, Proudman S, Foster D, Wiese M. Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. Sci Rep. 2020;10(1):18634.
CVIII. Yoo DH, Park W, Suh CH, Shim SC, Lee SJ, Bae YJ, et al. Rituximab is effective in the treatment of rheumatoid arthritis regardless of body mass index.Ann Rheum Dis. 2017;76(Suppl. 2):548.
CIX. Gialouri C, et al. Pappa M, Evangelatos G, Nikiphorou E, Fragoulis G. Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review. Autoimmun Rev. 2023;22(7):103357.
CX. Shan J, Zhang J. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis. Joint Bone Spine. 2019;86(2):173-83.
CXI. Wasko MC, Kay J, Hsia EC, Rahman MU. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res (Hoboken). 2011;63(4):512-21.
CXII. Burska AN, Sakthiswary R, Sattar N. Effects of tumour necrosis factor antagonists on insulin sensitivity/ resistance in rheumatoid arthritis: A systematic review and meta-analysis. PLoS One. 2015;10(6):e0128889.
CXIII. Rempenault C, Combe B, Barnetche T, Gaujoux-Viala C, Lukas C, Morel J, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and metaanalysis. Ann Rheum Dis. 2018;77(1):98-103.
CXIV. Baghdadi LR. Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients. A systematic review and meta-analysis. PLoS One. 2020;15(7):e0235637.
CXV. Lin C, Ji H, Cai X, Yang W, Lv F, Ji L. The association between the biological disease-modifying antirheumatic drugs and the incidence of diabetes: A systematic review and meta-analysis. Pharmacol Res. 2020;161:105216.
CXVI. Paul SK, Montvida O, Best JH, Gale S,Schramm AP, Sarsour K. Association of biological antirheumatic therapy with risk for type 2 diabetes: a retrospective cohort study in incident rheumatoid arthritis. BMJ Open. 2021;11(6):e042246.
CXVII. Ruscitti P, Masedu F, Alvaro S, Airò P, Battafarano N, Cantarini L, et al. Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLoS Med. 2019;16(9):e1002901.
CXVIII. Desai RJ, Dejene S, Jin Y,Liu J, Kim SC. Comparative risk of diabetes mellitus in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying drugs. A cohort study. ACR Open Rheumatol. 2020;2(4):222-31.
CXIX. Ursini F, Russo E, Hribal ML, Mauro D, Savarino F, Bruno C, et al. Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine (Baltimore). 2015;94(21):e888.
CXX. van Lint JA, van Hunsel FPAM, Tas SW, Vonkeman HE, Hoentjen F, van Doorn MBA, et al. Hypoglycaemia following JAK inhibitor treatment in patients with diabetes. Ann Rheum Dis. 2022;81(4):597-9.
CXXI. Xie W, Yang X, Ji LL, Zhang Z. Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2020;50(4):598-607.
CXXII. Ozen G, Pedro S, Holmqvist ME, Avery M, Wolfe F, Michaud K. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Ann Rheum Dis. 2017;76(5):848-54.
CXXIII. Mann DL, McMurray JJV, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure. Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109(13):1594-602.
CXXIV. Setoguchi S, Schneeweiss S, Avorn J, Katz JN, Weinblatt ME, Levin R, et al. Tumor necrosis factor-α antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008;156(2):33641.
CXXV. Heslinga SC, Van Sijl AM, De Boer K, Van Halm VP, Nurmohamed MT. Tumor necrosis factor blocking therapy and congestive heart failure in patients with inflammatory rheumatic disorders: a systematic review. Curr Med Chem. 2015;22(16):1892-902.
CXXVI. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res. 2011;63(4):522-9.
CXXVII. Lee YH, Bae SC, Song GG. Hepatitis B virus (VHB) reactivation in rheumatic patients with hepatitis core antigen (VHB occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol. 2013;31(1):118-21.
CXXVIII. Lee YH, Bae SC, Song GG. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. Int J Rheum Dis. 2013;16(5):527-31.
CXXIX. Cantini F, Boccia S, Goletti D, Iannone F, Leoncini E, Panic N, et al. VHB reactivation in patients treated with antitumor necrosis factor-alpha (TNF-α) agents for rheumatic and dermatologic conditions: A systematic review and metaanalysis. Int J Rheumatol. 2014; 2014: 926836.
CXXX. van Vollenhoven R, Emery P, Bingham III C, Keystone E, Fleischmann R, Furst D, et al. Long-term safety of rituximab: pooled analysis of the rheumatoid arthritis global clinical trial programme over 11 years. Rheumatology 2014;53(Suppl 1):i97-i98.
CXXXI. Vassilopoulos D, Delicha EM, Settas L, Andrianakos A, Aslanidis S, Boura P, et al. Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study. Clin Exp Rheumatol. 2016;34(5):893-900.
CXXXII. Padovani M, Filipini M, Tincani A, Lanciono E, BruscheI E, Epis O, et al. Safety of abatacept in rheumatoid arthritis with serologic evidence of past or present hepatitis B virus infection. Arthritis Care Res. 2016;68(6):738-43.
CXXXIII. Ismajli M, Ionescu R, Moore S, Leandro M. Long-term use of rituximab in rheumatoid arthritis: 17 years followup. Rheumatology (Oxford). 2017;56(Suppl 2):ii142.
CXXXIV. Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, et al. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis. 2017;76(6):1051-6.
CXXXV. Moghoofei M, Mostafaei S, Ashraf-Ganjouei A, Kavosi H, Mahmoudi M. VHB reactivation in rheumatic diseases patients under therapy: A meta-analysis. Microb Pathog. 2018;114:436-43.
CXXXVI. Chen YN, Huang WN, Wu YD, Lin CT, Chen YH, Chen DY, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib:
a real-world study. Ann Rheum Dis. 2018;77(5):780-2.
CXXXVII. Hsieh T-Y, Dickson C, Wu W-S, De La Torre I, Liao R, Winthrop K, et al. Hepatic safety in patients with rheumatoid arthritis treated with baricitinib: post-hoc analysis from clinical studies. Int J Rheum Dis. 2019;22(53):174-5.
CXXXVIII. Chen MH, Lee I-C, Chen MH, Hou MC, Tsai CY, Huang YH. Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. Ann Rheum Dis 2021;80(11):1393-9.
CXXXIX. Zhong Z, Liao W, Dai L, Feng X, Su G, Gao Y, et al. Average corticosteroid dose and risk for VHB reactivation and hepatitis flare in patients with resolved Hepatitis B infection. Ann Rheum Dis. 2022;81(4):584-91.
CXL. Hong X, Xiao Y, Xu L, Liu L, Mo H, Mo H. Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis. A meta-analysis. Immun Inflamm Dis. 2023;11(2):e780.
CXLI. Fragoulis GE, Dey M, Zhao S, Schoones J, Courvoisier D, Galloway J, et al. Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. RMD Open. 2022;8(2):e002726.
CXLII. Fragoulis GE, Nikiphorou E, Dey M, Zhao S, Courvoisier D, Laurent A, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023;82(6):742-53.
CXLIII. Sebastiani M, Atzeni F, Milazzo L, Quartuccio L, Scirè C, Gaeta GB, et al. Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. Joint Bone Spine. 2017;84(5):525-30.
CXLIV. Martín-Mola E, Hernández B, García-Arias M, ÁlvaroGracia JM, Balsa A, Reino JG, et al. Consenso de uso de rituximab en artritis reumatoidea. Un documento con recomendaciones basadas en la evidencia. Reumatol Clin. 2011;7(1):30-44.
CXLV. Nunes J, Marinho RT, Fonseca JE, Pereira da Silva JA, Velosa J. Prophylaxis of hepatitis B reactivation with immunosuppressive therapy in rheumatic diseases. Orientations for clinical practice. Acta Reumatol Port. 2011;36(2):110-8.
CXLVI. Maneiro JR, Souto A, Gomez-Reino JJ. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, metaanalysis, and network meta-analysis. Semin Arthritis Rheum. 2017;47(2):149-56.
CXLVII. Tank ND, Karelia B, Vegada B. Biological response modifiers in rheumatoid arthritis: systematic review and meta-analysis of safety. J Pharmacol Pharmacother. 2017;8(3):92-105.
CXLVIII. De La Forest Divonne M, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers. Joint Bone Spine. 2017;84(2):133-40.
CXLIX. Singh JA, Hossain A, Mudano AS, Tanjong Ghogomu E, Suarez‐Almazor ME, Buchbinder R, et al. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network metaanalysis. Cochrane Database Syst Rev. 2017;5(5):CD012657.
CL. Huang F, Luo ZC. Risk of adverse drug events observed with baricitinib 2 mg versus baricitinib 4 mg once daily for the treatment of rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. BioDrugs. 2018;32(5):415-23.
Derechos de autor 2025 a nombre de los autores. Derechos de reproducción: Sociedad Argentina de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
